Solésence (NASDAQ: SLSN) outlines CEO Jess Jankowski separation terms
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Solésence, Inc. disclosed details of a separation agreement with former CEO Jess Jankowski following his previously reported resignation as an officer. Under the agreement, effective December 2, 2025, Jankowski will receive severance pay totaling $366,912, accelerated vesting of all his outstanding stock options, and continued company-paid health insurance premiums under COBRA for the duration of the severance period. In return, he is providing a broad release of claims against the company and reaffirming obligations such as restrictive covenants and assistance in certain potential disputes. The separation agreement is filed as an exhibit to this report, with some portions redacted as confidential.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
FAQ
What did Solésence (SLSN) announce in this 8-K filing?
Solésence, Inc. announced that it entered into a Separation Agreement and General Release with former CEO Jess Jankowski, detailing his severance and related terms following his resignation as an officer.
How much severance is Solésence (SLSN) paying former CEO Jess Jankowski?
Under the separation agreement, former CEO Jess Jankowski will receive severance pay totaling $366,912.
How will Solésence (SLSN) handle health insurance for former CEO Jess Jankowski?
For the period during which severance is paid, Solésence will pay the monthly insurance premiums for Jess Jankowski’s participation in the company’s group health insurance plan through COBRA.
What does Jess Jankowski agree to in exchange for the Solésence (SLSN) separation benefits?
In exchange, Jess Jankowski agrees to release all claims against Solésence and its representatives, continue complying with restrictive covenants, and assist the company, at its request, in certain potential disputes.
Where can investors find the full terms of the Solésence (SLSN) separation agreement?
The full terms are in Exhibit 10.1 to the report, titled “Confidential Separation Agreement and Release, dated November 24, 2025,” with some confidential portions redacted.